| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
|
| ln Vitro |
In WB-F344 cells, thioacetamide (TAA; 0–10,000 μM; 24 h) exhibits concentration-dependent cytotoxicity[4]. In the early stages, at low (1000 μM) and high (10000 μM) concentrations, thioacetamide (TAA; 1000 and 10000 μM; 0-24 h; WB-F344 cells) contains differentially-expressed genes[4].
|
|---|---|
| ln Vivo |
In male ICR mice, thioacetamide (TAA; 100 mg/kg; i.p., three times per week) can cause chronic liver fibrosis[2]. In C57BL/6 mice, thioacetamide (200–1200 mg/kg; intraperitoneal; once) causes a hepatic encephalopathy model [3].
|
| Cell Assay |
Cell Viability Assay[4]
Cell Types: WB-F344 cells Tested Concentrations: 0-10000 μM Incubation Duration: 24 hrs (hours) Experimental Results: Had 20% and 50% cell death at the 1000 and 10000 μM concentrations, respectively. |
| Animal Protocol |
Animal/Disease Models: Male ICR mice[2]
Doses: 100 mg/kg Route of Administration: intraperitoneal (ip)injection; three times weekly for eight weeks Experimental Results: Induced chronic liver fibrosis in male ICR mice and resulted in lower body weight, serum cholesterol and triglycerides as well as increased liver size, ALT, AST and LDH values. Animal/Disease Models: Male C57BL/6 mice (20-25g, aged 8-12 weeks )[3] Doses: 200, 600, and 1,200 mg/kg Route of Administration: intraperitoneal (ip)injection; once Experimental Results: Altered the neuropsychiatric state, motor behavior and reflex and sensory functions. Increased in the glutamate release in the cerebral cortex of Hepatic encephalopathy (HE ) mice. |
| References |
[1]. Wallace MC, et, al. Standard operating procedures in experimental liver research: thioacetamide model in mice and rats. Lab Anim. 2015 Apr;49(1 Suppl):21-9.
[2]. Chen IS, et, al. Hepatoprotection of silymarin against thioacetamide-induced chronic liver fibrosis. J Sci Food Agric. 2012 May;92(7):1441-7. [3]. Miranda AS, et, al. A thioacetamide-induced hepatic encephalopathy model in C57BL/6 mice: a behavioral and neurochemical study. Arq Neuropsiquiatr. 2010 Aug;68(4):597-602. [4]. Yeom HJ, et, al. Expression analysis of early response-related genes in rat liver epithelial cells exposed to thioacetamide in vitro. J Vet Med Sci. 2009 Jun;71(6):719-27. |
| Molecular Formula |
C2H5NS
|
|---|---|
| Molecular Weight |
75.13
|
| CAS # |
62-55-5
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
S=C(C([H])([H])[H])N([H])[H]
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (1331.03 mM)
H2O : 50 mg/mL (665.51 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (33.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (33.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (33.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 13.3103 mL | 66.5513 mL | 133.1026 mL | |
| 5 mM | 2.6621 mL | 13.3103 mL | 26.6205 mL | |
| 10 mM | 1.3310 mL | 6.6551 mL | 13.3103 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
